ESLOF Quote, Financials, Valuation and Earnings

DBV Technologies SA has a net margin of -- compared to Essilorluxottica's net margin of --. Essilorluxottica's return on equity of -- beat DBV Technologies SA's return on equity of --.

Essilorluxottica has a consensus price target of --, signalling downside risk potential of --. On the other hand DBV Technologies SA has an analysts' consensus of -- which suggests that it could grow by 590.04%. Given that DBV Technologies SA has higher upside potential than Essilorluxottica, analysts believe DBV Technologies SA is more attractive than Essilorluxottica.

Essilorluxottica has a beta of 0.965, which suggesting that the stock is 3.456% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of 0.642, suggesting its less volatile than the S&P 500 by 35.828%.

Essilorluxottica has a quarterly dividend of $4.25 per share corresponding to a yield of 1.77%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Essilorluxottica pays 21.28% of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend. Essilorluxottica's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Essilorluxottica quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Essilorluxottica's net income of -- is lower than DBV Technologies SA's net income of -$30.4M. Notably, Essilorluxottica's price-to-earnings ratio is 39.05x while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Essilorluxottica is 3.96x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Genfit SA has a net margin of -- compared to Essilorluxottica's net margin of --. Essilorluxottica's return on equity of -- beat Genfit SA's return on equity of --.

Essilorluxottica has a consensus price target of --, signalling downside risk potential of --. On the other hand Genfit SA has an analysts' consensus of -- which suggests that it could grow by 170.55%. Given that Genfit SA has higher upside potential than Essilorluxottica, analysts believe Genfit SA is more attractive than Essilorluxottica.

Essilorluxottica has a beta of 0.965, which suggesting that the stock is 3.456% less volatile than S&P 500. In comparison Genfit SA has a beta of 1.145, suggesting its more volatile than the S&P 500 by 14.458%.

Essilorluxottica has a quarterly dividend of $4.25 per share corresponding to a yield of 1.77%. Genfit SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Essilorluxottica pays 21.28% of its earnings as a dividend. Genfit SA pays out -- of its earnings as a dividend. Essilorluxottica's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Essilorluxottica quarterly revenues are --, which are smaller than Genfit SA quarterly revenues of --. Essilorluxottica's net income of -- is lower than Genfit SA's net income of --. Notably, Essilorluxottica's price-to-earnings ratio is 39.05x while Genfit SA's PE ratio is 33.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Essilorluxottica is 3.96x versus 2.75x for Genfit SA. Usually stocks with elevated PS ratios are considered overvalued.

Innate Pharma SA has a net margin of -- compared to Essilorluxottica's net margin of --. Essilorluxottica's return on equity of -- beat Innate Pharma SA's return on equity of -72.79%.

Essilorluxottica has a consensus price target of --, signalling downside risk potential of --. On the other hand Innate Pharma SA has an analysts' consensus of $7.25 which suggests that it could grow by 263.33%. Given that Innate Pharma SA has higher upside potential than Essilorluxottica, analysts believe Innate Pharma SA is more attractive than Essilorluxottica.

Essilorluxottica has a beta of 0.965, which suggesting that the stock is 3.456% less volatile than S&P 500. In comparison Innate Pharma SA has a beta of 0.290, suggesting its less volatile than the S&P 500 by 71.016%.

Essilorluxottica has a quarterly dividend of $4.25 per share corresponding to a yield of 1.77%. Innate Pharma SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Essilorluxottica pays 21.28% of its earnings as a dividend. Innate Pharma SA pays out -- of its earnings as a dividend. Essilorluxottica's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Essilorluxottica quarterly revenues are --, which are smaller than Innate Pharma SA quarterly revenues of --. Essilorluxottica's net income of -- is lower than Innate Pharma SA's net income of --. Notably, Essilorluxottica's price-to-earnings ratio is 39.05x while Innate Pharma SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Essilorluxottica is 3.96x versus 6.15x for Innate Pharma SA. Usually stocks with elevated PS ratios are considered overvalued.